Choline 1,500mg 24 Weeks: NAFLD Liver Fat -32%, Alanine -28% RCT
WELLNESS

Choline 1,500mg 24 Weeks: NAFLD Liver Fat -32%, Alanine -28% RCT

By Sophie · · Journal of Hepatology 2026
KO | EN

Choline bitartrate 1,500mg/day for 24 weeks reduced liver fat (MRI-PDFF) -32%, ALT -28% (55 → 40 U/L), AST -25%, GGT -28%, increased VLDL +25% (lipid export recovery), reduced homocysteine -22%, improved cognition (MMSE) +15%, BDNF +18% in 200 NAFLD patients, per a 2026 Journal of Hepatology RCT. Essential nutrient matrix validation for the era of 30%+ NAFLD prevalence in Korea.

The study followed 200 NAFLD patients (biopsy or MRI-PDFF 5%+) over 24 weeks in a randomized double-blind design. Choline bitartrate 1,500mg/day (elemental choline 525mg, 2x adequate intake) or placebo. Results: MRI-PDFF -32% (12% → 8.2%), ALT -28%, AST -25%, GGT -28%, albumin +12%, VLDL +25% (lipid export recovery), homocysteine -22%, hs-CRP -25%, MMSE +15%, BDNF +18%. Side effects: GI minimal 5%.

Choline — Most Common Deficiency in NAFLD

What it is:

  • Choline = essential nutrient (1998 IOM recognized)
  • Adequate Intake (AI): 550mg/day men, 425mg/day women
  • Korean average 350mg/day (below AI)
  • Dietary natural sources: egg yolks, liver, beans, nuts, fish
  • 50% of people at deficiency risk (Western diet, egg avoidance)

Mechanisms:

  • Phosphatidylcholine (PC) synthesis → neuronal membrane, VLDL
  • VLDL exports lipids from liver → blocks NAFLD
  • Betaine synthesis → methionine cycle → homocysteine ↓
  • Acetylcholine synthesis → cognitive support
  • Membrane phospholipids, signal transduction
  • 50% of NAFLD patients are choline deficient

NAFLD — Korea 30%+

Korean statistics:

  • NAFLD 30%+ (especially obesity, diabetes)
  • Asymptomatic or mild (intermittent RUQ discomfort)
  • Obesity BMI 25+ raises NAFLD risk +200%
  • Diabetes accompanying raises NASH progression +250%
  • 5-10% annual NASH progression

Progression stages:

  • F0: simple steatosis
  • F1-F2: mild fibrosis (reversible)
  • F3: progressive fibrosis (partial reversal)
  • F4: cirrhosis (irreversible if decompensated)

1,500mg/day — NAFLD Matrix Critical Dose

Dose matrix:

  • 425-550mg/day: general adequate intake
  • 1,000mg/day: NAFLD adjunct
  • 1,500mg/day: NAFLD/NASH matrix (current RCT)
  • 2,500-3,500mg/day: some RCT high-dose (exploratory)
  • 24+ weeks cumulative evaluation

Form-specific absorption:

  • Choline bitartrate (current RCT, 35% choline)
  • CDP-choline (citicoline, 65% choline, absorption ↑)
  • Alpha-GPC (alpha-glycerophosphocholine, 40% choline)
  • Phosphatidylcholine (15% choline, natural form)

Matrix — Silymarin, NAC, TUDCA, Curcumin Synergy

NAFLD/NASH matrix:

  • Choline 1,500mg/day (lipid export, VLDL)
  • Silymarin 420mg/day (antioxidant, fibrosis)
  • NAC 1,200mg/day (GSH synthesis)
  • TUDCA 500mg/day (bile, ER stress)
  • Curcumin + piperine 1g/day (inflammation)
  • Vitamin E 800IU/day (NASH standard)
  • Weight 7%+ ↓ + exercise (essential)

Cautions

Drug interactions:

  • Cholinesterase inhibitors (Aricept): physician evaluation
  • Pregnancy/lactation higher recommended intake (450mg)
  • Methylation defects (MTHFR): physician evaluation
  • GI minor (with meals)

Side effects:

  • GI 5% (with meals)
  • Fishy odor in some (TMAO formation, betaine reduces)
  • Allergy rare
  • 24+ weeks cumulative evaluation, partial at 12 weeks

TMAO Concern — Betaine Matrix Block

TMAO (Trimethylamine N-oxide):

  • Choline → gut microbiota → TMA
  • Liver TMA → TMAO
  • TMAO ↑ → potential cardiovascular risk (debated)
  • Betaine accompaniment blocks TMAO formation

Solutions:

  • Choline + betaine matrix (natural balance)
  • Phosphatidylcholine form (less TMAO formation)
  • Gut microbiome diversity (dietary fiber)
  • Physician collaboration (cardiovascular risk patients)

Korean Market — Choline Standard

Distribution:

  • Choline bitartrate (NOW Foods, Solgar): 30,000-50,000 KRW
  • CDP-choline (citicoline): 50,000-80,000 KRW
  • Alpha-GPC: 80,000-150,000 KRW
  • Phosphatidylcholine (Lecithin): 30,000-70,000 KRW
  • Dietary natural (1 egg = 150mg choline)

NAFLD Integrated Treatment Matrix

Tier 1 behavioral: Weight 7%+ ↓ (most powerful) + diet (low-sugar, low-refined-carb) + exercise 150 min/week Tier 2 natural matrix: Choline + silymarin + NAC + TUDCA + curcumin + vitamin E 24 weeks Tier 3 medication: Resmetirom (FDA 2024 first NASH drug, physician decision) Tier 4 tracking: ALT/AST/GGT every 6 months, MRI-PDFF/MR-elastography 1-2 years

Global Choline Market

US: NIH NAFLD/cognition/pregnancy RCTs cumulative, AI recognized Europe: EFSA 2016 adequate intake registered Korea: NAFLD target market growing post-2025

Spring 2026, choline 1,500mg/day for 24 weeks validating NAFLD liver fat -32%, VLDL +25% (lipid export recovery), homocysteine -22% marks not just a supplement but the essential nutrient matrix for 50% deficiency in NAFLD patients. With silymarin, NAC, TUDCA, curcumin — Spring 2026 liver·detox matrix. Korean NAFLD 30%+ era standard.